PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
30.16
Positive P/E while Medical - Pharmaceuticals median is negative at -2.14. Peter Lynch would investigate competitive advantages in a distressed Medical - Pharmaceuticals.
3.14
P/S less than half the Medical - Pharmaceuticals median of 11.42. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
4.73
P/B 1.1-1.25x Medical - Pharmaceuticals median of 4.19. John Neff would demand superior ROE to justify premium.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.73
Fair value ratio 1.1-1.25x Medical - Pharmaceuticals median of 4.07. John Neff would demand superior metrics to justify premium.
0.83%
Positive earnings while Medical - Pharmaceuticals median shows losses. Peter Lynch would examine earnings quality advantage.
No Data
No Data available this quarter, please select a different quarter.